Regencell Bioscience Holdings RGC

Regencell Bioscience Holdings Limited is a holding company incorporated in the Cayman Islands. The company owns wholly owned subsidiaries including Regencell Bioscience Limited in Hong Kong Regencell Limited in Hong Kong and Regencell Bioscience North America Limited in the British Virgin Islands. Regencell Bioscience Holdings Limited is an early stage bioscience company that focuses on the research development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders specifically attention deficit hyperactivity disorder and autism spectrum disorder. Its principal executive offices are located in Causeway Bay Hong Kong.

We plan to generate revenue from the commercialization of our standardized TCM formula for ADHD and ASD patients. Revenue will come from the sale of pCm formula products once they receive regulatory approval in Hong Kong and other jurisdictions. Additionally we may earn income through licensing agreements partnerships or joint ventures that facilitate production and distribution.

Regencell Bioscience Holdings Limited occupies a niche position in the TCM industry as one of the few companies focusing on a standardized TCM formula for ADHD and ASD. The ADHD and ASD treatment market is dominated by pharmaceutical companies such as Eli Lilly Novartis Pfizer Teva and Shire which provide stimulant and non stimulant medications. Unlike those pharmaceutical firms we do not compete directly with approved drug manufacturers because our product is a natural herbal treatment. The TCM market for ADHD and ASD in Hong Kong is highly fragmented with no large TCM competitor identified. Our competitive advantages include exclusive rights to the TCM practitioner's formula intellectual property protection through trademarks and trade secrets and lower research and development costs compared with traditional drug development.

The company intends to serve patients diagnosed with ADHD and ASD as well as their families and caregivers. Initial commercial efforts will target the Hong Kong market with plans to expand to other countries such as the United States after obtaining necessary approvals. No specific customer names are disclosed in the filing.